Wednesday, October 30, 2024

This Drug Giant's Dividend Isn't as Scary as It Looks

Shield

AN OXFORD CLUB PUBLICATION

Loyal reader since January 2024

Wealthy Retirement

View in browser

SPONSORED

HUGE Overnight Trade Opportunity During Election Week?!

WAR Election - Open House
 

I closed biggest Overnight Trades during just ONE week: 214%... 190%... and as much as 293% gains...

But the week of the election could bring the BIGGEST opportunities yet!

For the first time ever... you can join our FREE Open House during Election Week (November 4 - 8).

You can get ALL of our trade recommendations (including the Overnight Trades)...

Plus... we'll have a Post Election Livestream Trading Event!

Go Here to Join Us for Free (No Cost... No Obligation... No BS!)

This Drug Giant's Dividend Isn't as Scary as It Looks

Marc Lichtenfeld, Chief Income Strategist, The Oxford Club

Marc Lichtenfeld

Since Halloween is tomorrow, in this week's Safety Net, we're going to take a look at a dividend that many investors are afraid of.

For as long as I can remember, Wall Street has been scared silly about AbbVie (NYSE: ABBV).

The rub on AbbVie is that Humira, the company's top revenue generator and the biggest-selling drug in the world, is now off-patent. For many years, Wall Street analysts advised investors to stay away, warning that when Humira's patent expired, generics would flood the market and cause AbbVie's revenue, earnings, and stock price to crater as a result.

But in reality, the company is as terrifying as a polite 4-year-old trick-or-treater in a princess costume.

The chart below shows how wrong Wall Street analysts have been about AbbVie.

Chart: AbbVie (NYSE: ABBV)
View larger image
 

Even now, more than a third of analysts that cover the stock don't rate it a "Buy." But I never let the "Wrong Way Corrigan" analysts influence me.

AbbVie has been in the Compound Income Portfolio in my monthly newsletter, The Oxford Income Letter, since 2016. With dividends reinvested, we're sitting on a gain of 376% and enjoying an annual yield of 10.8% on our original investment.

AbbVie is a Perpetual Dividend Raiser, having boosted its dividend every year since it was spun off from Abbott Laboratories (NYSE: ABT) in 2013. It currently pays shareholders a quarterly dividend of $1.55 per share, which gives the stock a 3.3% yield on the current price.

Can AbbVie continue to be a Perpetual Dividend Raiser?

SPONSORED

Get Marc's Top 5 Dividend Stocks (FREE PICKS)

World-renowned income expert Marc Lichtenfeld just released his Ultimate Dividend Package. Inside, you'll find his TOP FIVE dividend stocks right now.

And today, he's giving you this package... completely free of charge!

To get your FREE dividend recommendations, click here now.

In the second quarter, Humira sales dropped 29% year over year.

As a result, the company's free cash flow is forecast to decline from $22.1 billion last year to $17.6 billion in 2024.

However, AbbVie is only expected to pay $11.1 billion in dividends for a payout ratio of 63%, which is well within my comfort range. I like to see companies' payout ratios stay below 75% of their free cash flow. That tells me that even if free cash flow declines, the company should be able to afford its dividend going forward.

Plus, as I said above, AbbVie has boosted its dividend every year for 11 years, showing investors its commitment to dividend growth.

Chart: A Not-So-Scary Dividend - AbbVie's annual dividend per share
View larger image
 

Considering all of that - the decline in Humira sales, the payout ratio, the dividend track record, etc. - what grade would you give AbbVie's dividend?

Click the button below to let me know your thoughts in the comments. Then scroll up to reveal my dividend safety rating.

Share Your Grade Here!

Discover the Top Passive Income Opportunity for 2024...

Election Scenarios and Their Impact on Markets

Former CBOE Trading Legend Showed Members 246% Total Gains While the S&P Was Down 20% During the COVID Crash. Now He's Hosting a Free Class Revealing the Answer to Big Wins. Click for More!

Does the American Dream Really Cost $4.4 Million?

SPONSORED

Discover the Hidden Gold Play Wall Street Is Ignoring

While everyone is chasing gold at $2,500 per ounce, there's a little-known investment that gives you exposure to over 1 oz of gold — for less than $20. And the best part? It has outperformed gold by 10-to-1 over the past 25 years.

Click here now to seize this opportunity before the next surge.

What Are Buffett, Dalio, and Druckenmiller So Worried About?

U.S. Market has quietly entered the 'Dead Zone' Dear Reader, As the market hits new highs... and the general public is feeling ...